Cornell University · Microbiology & ImmunologyTuberculosis Therapeutics Unit
Brian C Vanderven · Ithaca, New York
Research Focus
Dr. Brian Vanderven's lab at Cornell University focuses on developing new treatments for tuberculosis (TB) by targeting the bacterial mechanisms that allow TB to persist in the body. The lab is researching compounds that can stimulate cAMP production in the bacterium Mycobacterium tuberculosis, potentially blocking its ability to metabolize lipids and thus improving drug efficacy. Their ultimate goal is to shorten TB treatment regimens and combat drug resistance.
tuberculosiscAMPMycobacterium tuberculosisdrug resistancelipid metabolismantibioticschemical screeningtherapeutics
Research Aims
3AIM 01Characterize how cAMP stimulating compounds block lipid metabolism in Mycobacterium tuberculosis.
AIM 02Identify novel cAMP stimulators and their molecular targets.
AIM 03Evaluate the therapeutic potential of combining multiple cAMP stimulators with existing TB drugs.
Skills the Lab Values
high-throughput screeninganimal modelsbacterial culturechemical perturbation techniquesin vivo experimentsmolecular biology techniquesdrug efficacy evaluationsynergistic drug testingdata analysis
Output against the department
Publications52bottom 12% of dept.428th of 486
this lab
most publishedleast published
Citations3.8kbottom 28% of dept.352nd of 486
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.